PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Phase III, multicentre, randomized, double-blind, parallel group, long-term study
investigating the efficacy and safety of the 5mg and 10mg doses of PGL4001 for the treatment
of uterine myoma.